New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:15 EDTXON, ZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
News For ZIOP;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
10:29 EDTZIOP, XONOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
10:16 EDTXON, ZIOPHigh option volume stocks
Subscribe for More Information
May 19, 2015
11:59 EDTZIOP, XONOptions with decreasing implied volatilit
Subscribe for More Information
May 18, 2015
10:37 EDTZIOP, XONOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 14, 2015
05:52 EDTXON, ZIOPMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
10:02 EDTZIOPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with a Hold at Gabelli... Bellicum Pharmaceuticals (BLCM) initiated with a Neutral at Guggenheim... Criteo (CRTO) initiated with a Hold at Evercore ISI... FleetCor (FLT) initiated with a Buy at Monness Crespi... Franco-Nevada (FNV) initiated with a Buy at Canaccord... Horizon Technology (HRZN) initiated with an Outperform at Oppenheimer... Merrimack (MACK) initiated with a Buy at Guggenheim... Mobileye (MBLY) initiated with a Sector Weight at Pacific Crest... Monroe Capital (MRCC) initiated with an Outperform at Oppenheimer... Royal Gold (RGLD) initiated with a Hold at Canaccord... Silver Wheaton (SLW) initiated with a Buy at Canaccord... U.S. Concrete (USCR) initiated with a Buy at Stifel... Ziopharm (ZIOP) initiated with a Neutral at Guggenheim.
06:26 EDTZIOPZiopharm initiated with a Neutral at Guggenheim
May 12, 2015
09:23 EDTXON, ZIOPIntrexon CEO says Ziopharm acqusition could be 'attractive' in future
Subscribe for More Information
09:20 EDTXONOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTXONBofA/Merrill to hold a conference
Subscribe for More Information
05:55 EDTZIOP, XONIntrexon price target lowered to $45 from $50 at Mizuho
Subscribe for More Information
May 11, 2015
19:15 EDTXONOn The Fly: After Hours Movers
Subscribe for More Information
16:40 EDTZIOP, XONIntrexon declares special dividend of Ziopharm shares
Subscribe for More Information
16:36 EDTXONIntrexon reports Q1 EPS 25c, consensus (5c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use